Revance will wait to seek backing for Botox-rival

Revance Therapeutics Incwill wait to seek partnerships with bigger drugmakers until it is closer to regulatory approval for its Botox rival treatment, Chief Executive Dan Browne told Reuters in an interview.The California-based drug developer shook the aesthetic industry last week by reporting data that showed its drug RT002reduced the severity of frown lines for about six months, almost double the 3-4 months Botox and other treatments achieve.The news sent a shiver through investors who have be